Sign In
Buy BHVN
$10.81
+0.680 (+6.71%)
At Close: Jun 03, 2026
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
07:30am, Monday, 01'st Jun 2026
BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system disorders Fir
Biohaven: Despite Today's Gains, I Remain Skeptical
03:12pm, Wednesday, 27'th May 2026
Biohaven Ltd. shared an R&D presentation today in relation to its epilepsy asset and also updated on its degrader programs. BHVN - spun out of the original Biohaven after its acquisition by Pfizer - a
BHV-1300 demonstrated deep, rapid, and sustained lowering of pathogenic TSHR autoantibodies (TSHR-IgG1) in patients with Graves' hyperthyroidism receiving 1000 mg SC weekly, with mean reductions in TS
In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a generalized tonic-clonic seizure was 141 days in the opakali
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 05'th May 2026
Biohaven Ltd. (BHVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
04:02pm, Monday, 04'th May 2026
Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026. Advancement of high-value, late-stage priority programs: Piv
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026
04:07pm, Wednesday, 15'th Apr 2026
Biohaven Ltd. is downgraded from Strong Buy to Hold following the FDA's Complete Response Letter for troriluzole in Spinocerebellar Ataxia. BHVN pivots focus to three late-stage programs: MODE/TRAP de
Why Biohaven Stock Crushed it on Monday
05:41pm, Monday, 13'th Apr 2026
That pundit flagged the stock as a buy. He also expects it to more than double in price.
Aberdeen Group plc Buys Shares of 693,452 Biohaven Ltd. $BHVN
03:37am, Thursday, 09'th Apr 2026
Aberdeen Group plc bought a new stake in Biohaven Ltd. (NYSE: BHVN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The f
SG Americas Securities LLC Grows Holdings in Biohaven Ltd. $BHVN
04:47am, Wednesday, 08'th Apr 2026
SG Americas Securities LLC grew its holdings in shares of Biohaven Ltd. (NYSE: BHVN) by 291.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential
01:17pm, Monday, 23'rd Mar 2026
Sarissa Capital Management added 513,184 shares in Biohaven during the fourth quarter. The quarter-end position value increased by $5.79 million as a result of the transaction.
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of “Moderate Buy” by Brokerages
02:31am, Sunday, 22'nd Mar 2026
Biohaven Ltd. (NYSE: BHVN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seventeen brokerages that are covering the stock, MarketBeat.com reports. One equities rese
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
07:49pm, Saturday, 21'st Mar 2026
DAFNA Capital Management bought 720,000 shares of Biohaven in the fourth quarter; the estimated trade size was $8.92 million, based on average prices in the fourth quarter of 2025. Meanwhile, the quar
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
07:30am, Thursday, 19'th Mar 2026
Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026. Taldefgrobep is a novel inhi
What's Going On With Biohaven Stock On Monday?
11:47am, Monday, 09'th Mar 2026
Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong seizure reduction results.
